Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage
biopharmaceutical company developing novel nucleic acid therapeutics for
orphan diseases, today announced that Company management will present at
the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4,
2014 at 8:30 a.m. EDT in New York City.
A live audio webcast of the presentation will be available in the
Investors and Media section of Idera’s website at www.iderapharma.com
or at the link http://wsw.com/webcast/jeff82/IDRA.
An archived version will also be available on the Company’s website
after the event for 90 days.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company
developing a novel therapeutic approach for the treatment of genetically
defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera’s
proprietary technology involves creating novel nucleic acid therapeutics
designed to inhibit over-activation of Toll-like Receptors (TLRs). In
addition to its TLR programs, Idera is developing gene silencing
oligonucleotides (GSOs) that it has created using its proprietary
technology to inhibit the production of disease-associated proteins by
targeting RNA.
Copyright Business Wire 2014